BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,716 | +53.3% | 103 | 0.0% | 0.00% | – |
| Q2 2023 | $1,772 | +3.7% | 103 | 0.0% | 0.00% | – |
| Q1 2023 | $1,708 | +286.4% | 103 | +77.6% | 0.00% | – |
| Q4 2022 | $442 | -77.9% | 58 | -65.7% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 169 | +191.4% | 0.00% | – |
| Q2 2022 | $1,000 | -80.0% | 58 | -88.6% | 0.00% | -100.0% |
| Q1 2022 | $5,000 | -72.2% | 511 | -52.8% | 0.00% | -66.7% |
| Q4 2021 | $18,000 | +1700.0% | 1,082 | +4228.0% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 25 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 25 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | – | 25 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |